After getting beat up on its depression drug pitch, a battered Alkermes pivots to schizophrenia with a positive PhIII readout — but skeptics are ready to pounce
Badly needing a new focus after regulators and experts slapped around their pitch for the depression drug ALKS-5461, Alkermes $ALKS is changing the topic today …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
